Clinical stage biopharma, Xynomic Pharma, filed the paperwork for a new $65 Million offering. The company is developing small molecule treatments for several different cancer types. It trades on NASDAQ under the symbol “XYN.”
Xynomic has three candidates in development. Its lead candidate is being studied in Follicular Lymphoma (Ph II), Renal Cell Carcinoma (Ph III), Multiple Solid Tumors (Ph I), Diffuse Large B-Cell Lymphoma (planned Ph II).
The lead candidate, abexinostat, was in-licensed from Pharmacyclics, a subsidiary of AbbVie in February of 2017. Trials are underway for abexinostat in follicular lymphoma, as a monotherapy, in renal cell carcinoma, in combination with pazopanib, and in multiple solid tumors, in combination with Keytruda. In addition, the company plans to initiate four clinical trials of abexinostat in the next six months.